Email updates

Keep up to date with the latest news and content from BMC Urology and BioMed Central.

Open Access Highly Accessed Research article

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model

Salvador Arlandis-Guzman*, Carlos Errando-Smet, Jeffrey Trocio, Daniel Arumi and Javier Rejas

BMC Urology 2011, 11:9  doi:10.1186/1471-2490-11-9

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

mistake in figure 1

Javier Rejas   (2011-06-21 16:49)  Pfizer email

In figure 1, there is a mistake in the decision tree for patients treated with tolterodine and solifenacin. It is written that all patients are treated at the end of the study period with fesoterodine 4 mg but there is a mistake. Patients who started treatment with tolterodine or solifenacin discontinued or remained with the same treatment until the end of the study, they do not switched to fesoterodine.

Competing interests

None declared

top

Post a comment